rrMCL PI3K Inhibitor_ CITADEL-205 / INCB 50465-205 (#767)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
A phase 2, open-label, 2-cohort, multicenter study of INCB050465, a PI3K inhibitor, in relapsed or refractory Mantle Cell Lymphoma previously treated with or without a BTK inhibitor (CITADEL-205)
